Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - May 2013


3rd Serialization and Traceability for Brand Protection

09 May 2013 - 10 May 2013 - Philadelphia, PA, USA



Bookmark and Share


ExL Pharma’s 3rd Life Science Serialization and Traceability For Brand Protection is the premier event providing pharmaceutical & life science companies with comprehensive take-back-to-the-office serialization, traceability and e-pedigree strategies.

While there is a continued lack of federal guidance, it is still imperative to make the business case for your organization for brand protection purposes. If the supply chain partners are buttoned up throughout your drug’s journey to the customer, you are adding significant value to your brand by not allowing counterfeit or rogue drugs to damage your reputation.

The 2013 event will challenge the audience with new perspectives, speakers, formats and topics not often seen on the conference circuit, including:

Preparing pharma for California’s 2014/15 serialization mandate.

Learning from other industries:  How The Auto Industry Embraced and Integrated Serialization & Track & Trace

End to End Traceability doesn’t end with the wholesaler: Perspectives from pharmacies, hospitals and consumers on stage.

Top Reasons to Attend

This event prepares pharma for California's 2014 Serialization Mandate.

This event teaches pharma the business case for serialization and traceability in the most pain free and cost effective way

This event provides multiple perspectives throughout the supply chain- pharmacies, manufacturers and wholesalers.



Further information
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!